Skip to main content

dasatinib and nilotinib better than imatinib?

Well, two new studies have been published in the New England Journal of Medicine and were presented at the American Society of Clinical Oncology 2010 Annual Meeting.

Here's the story from Medscape:

These studies should lead to some vigorous debate in the clinical oncologists' community about how to treat CML (chronic myelogenous leukemia).

Gleevec (imatinib) remains a first-of-its-kind medicine. These new successors work on the same principle as imatinib. However, they seem to extend these principles and therefore are more effective.

It remains to be seen if the regulatory bodies will recommend these new kids on the block as first-line therapy for CML. Although, dasatinib and nilotinib have been around now for a few years.


Popular posts from this blog

Longforms and 'Best of 2017' Lists and Favorite Books by Ashutosh Joglekar and Scott Aaronson

Ashutosh Joglekar's books list. Scott Aaronson' list

Savita Bhabi

Well, it seems the Government of India is up to its usual censoring ways ... It's not as bad as what the Chinese are doing in battling Google. The Internet is awash in pornography and the feeble attempts of the Govt. of India won't be able to stem the tide. The Govt. should merely restrict itself to ensuring that there's no child pornography or trafficking of humans. There are problems galore for the Govt. to worry about as it is ...